OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
216059

GNI Group Ltd

Biotechnology & Medical ResearchVerified

GNI Group Ltd has a liquidity position that appears robust, with cash and equivalents amounting to ¥21.1 billion, which is significantly higher than its long-term debt of ¥5.4 billion. The company's current ratio of 4.25 indicates a strong ability to meet short-term obligations. However, the company reported negative operating cash flow of ¥2.4 billion and free cash flow of ¥7.6 billion, suggesting ongoing cash outflows from operations. Profitability metrics for GNI Group Ltd are negative, with a return on equity of -8.43% and a return on assets of -5.06%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income and net income were both negative, at ¥3.5 billion and ¥4.2 billion, respectively. These results are below the industry median for profitability metrics, indicating underperformance relative to its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification could expose the company to higher risk if demand in its primary market or product line declines. The company's revenue concentration is a concern, as it does not provide a clear breakdown of revenue by geographic region or customer segment. Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a mean price target of ¥4,400, with a median of ¥4,400 and a range from ¥3,800 to ¥5,000. The mean recommendation is 1.67, indicating a generally positive outlook, with one strong buy, two buy, and no hold ratings. However, the company's negative operating and free cash flows suggest that it may face challenges in sustaining growth without external financing or operational improvements. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow could indicate potential financial stress in the future. The company's debt-to-equity ratio of 0.11 is relatively low, suggesting that it is not heavily leveraged. Nevertheless, the company's capital expenditures of ¥1.6 billion indicate ongoing investment in its operations. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial statements and analyst reports do not mention any recent strategic initiatives or major business developments. The company's financial performance and risk profile suggest that it may need to focus on improving its profitability and cash flow generation to support long-term growth and stability.

30-day price · 2160(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGNI Group Ltd
Ticker2160.T
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. GNI Group Ltd is a Japanese company primarily engaged in healthcare diagnostics, offering products and services related to medical testing and diagnostic solutions.

Classification. GNI Group Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

GNI Group Ltd has a liquidity position that appears robust, with cash and equivalents amounting to ¥21.1 billion, which is significantly higher than its long-term debt of ¥5.4 billion. The company's current ratio of 4.25 indicates a strong ability to meet short-term obligations. However, the company reported negative operating cash flow of ¥2.4 billion and free cash flow of ¥7.6 billion, suggesting ongoing cash outflows from operations. Profitability metrics for GNI Group Ltd are negative, with a return on equity of -8.43% and a return on assets of -5.06%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income and net income were both negative, at ¥3.5 billion and ¥4.2 billion, respectively. These results are below the industry median for profitability metrics, indicating underperformance relative to its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification could expose the company to higher risk if demand in its primary market or product line declines. The company's revenue concentration is a concern, as it does not provide a clear breakdown of revenue by geographic region or customer segment. Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a mean price target of ¥4,400, with a median of ¥4,400 and a range from ¥3,800 to ¥5,000. The mean recommendation is 1.67, indicating a generally positive outlook, with one strong buy, two buy, and no hold ratings. However, the company's negative operating and free cash flows suggest that it may face challenges in sustaining growth without external financing or operational improvements. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow could indicate potential financial stress in the future. The company's debt-to-equity ratio of 0.11 is relatively low, suggesting that it is not heavily leveraged. Nevertheless, the company's capital expenditures of ¥1.6 billion indicate ongoing investment in its operations. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial statements and analyst reports do not mention any recent strategic initiatives or major business developments. The company's financial performance and risk profile suggest that it may need to focus on improving its profitability and cash flow generation to support long-term growth and stability.
Key takeaways
  • GNI Group Ltd has a strong liquidity position with significant cash reserves but is experiencing negative operating and free cash flows.
  • The company's profitability metrics are negative, indicating underperformance relative to industry standards.
  • Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
  • Analysts have a generally positive outlook, with a mean price target of ¥4,400 and a mean recommendation of 1.67.
  • The company's risk profile is low in terms of liquidity and dilution, but its financial performance suggests potential challenges in sustaining growth.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$26.84B
Gross profit$19.99B
Operating income-$3.47B
Net income-$4.24B
R&D
SG&A
D&A
SBC
Operating cash flow-$2.41B
CapEx-$1.56B
Free cash flow-$7.57B
Total assets$83.79B
Total liabilities$33.47B
Total equity$50.32B
Cash & equivalents$21.10B
Long-term debt$5.37B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$26.84B-$3.47B-$4.24B-$7.57B
FY-1$23.61B$1.40B$1.10B-$563.0M
FY-2$26.01B$13.11B$8.09B$8.11B
FY-3$17.42B$1.38B$388.8M-$2.29B
FY-4$12.69B$1.62B$1.07B-$407.0M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$83.79B$50.32B$21.10B
FY-1$71.94B$36.45B$10.12B
FY-2$62.39B$33.79B$21.63B
FY-3$33.91B$20.97B$11.05B
FY-4$30.30B$18.86B$14.35B
PeriodOCFCapExFCFSBC
FY0-$2.41B-$1.56B-$7.57B
FY-1-$3.16B-$1.54B-$563.0M
FY-2$6.55B-$2.08B$8.11B
FY-3$393.3M-$1.94B-$2.29B
FY-4$552.3M-$694.4M-$407.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$5.53B-$2.75B-$2.13B-$4.00B
FQ-1$7.48B-$2.97B-$3.75B-$5.14B
FQ-2$7.10B$682.5M$420.4M$294.5M
FQ-3$6.93B-$407.2M-$385.1M-$1.37B
FQ-4$5.32B-$772.3M-$530.3M-$1.36B
FQ-5$6.42B-$940.5M-$206.8M-$605.3M
FQ-6$5.46B$580.7M$975.0M$455.9M
FQ-7$5.79B-$521.7M-$1.12B-$1.62B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$82.59B$50.03B$19.87B
FQ-1$83.79B$50.32B$21.10B
FQ-2$82.60B$50.05B$22.78B
FQ-3$67.72B$35.27B$10.52B
FQ-4$68.00B$34.10B$9.93B
FQ-5$71.94B$36.45B$10.12B
FQ-6$62.75B$33.09B$14.05B
FQ-7$68.99B$36.83B$16.31B
PeriodOCFCapExFCFSBC
FQ0-$415.0M-$933.0M-$4.00B
FQ-1-$2.41B-$1.56B-$5.14B
FQ-2-$707.0M-$1.18B$294.5M
FQ-3-$931.7M-$922.6M-$1.37B
FQ-4-$287.8M-$371.2M-$1.36B
FQ-5-$3.16B-$1.54B-$605.3M
FQ-6-$2.06B-$1.19B$455.9M
FQ-7-$1.47B-$719.5M-$1.62B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$50.32B
Net cash$15.74B
Current ratio4.2
Debt/Equity0.1
ROA-5.1%
ROE-8.4%
Cash conversion57.0%
CapEx/Revenue-5.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 254 companies
Metric2160Activity
Op margin-12.9%7.0% medp25 3.8% · p75 10.2%bottom quartile
Net margin-15.8%2.4% medp25 -0.6% · p75 5.4%bottom quartile
Gross margin74.5%50.1% medp25 23.6% · p75 72.3%top quartile
CapEx / revenue-5.8%-6.8% medp25 -27.8% · p75 -1.7%above median
Debt / equity11.0%140.5% medp25 104.0% · p75 177.0%bottom quartile
Observations
IR observations
Mean price target4,400.00 JPY
Median price target4,400.00 JPY
High price target5,000.00 JPY
Low price target3,800.00 JPY
Mean recommendation1.67 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate49.70 JPY
Last actual EPS-84.08 JPY
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 00:14 UTCJob: 9f467b8d